Brokers Offer Predictions for Pacira BioSciences, Inc.’s Q1 2021 Earnings (NASDAQ:PCRX)


Share on StockTwits

Pacira BioSciences, Inc. (NASDAQ:PCRX) – Equities research analysts at Wedbush cut their Q1 2021 earnings per share (EPS) estimates for Pacira BioSciences in a note issued to investors on Wednesday, April 7th. Wedbush analyst L. Moussatos now anticipates that the company will earn $0.41 per share for the quarter, down from their previous estimate of $0.60. Wedbush also issued estimates for Pacira BioSciences’ Q3 2021 earnings at $0.65 EPS and FY2021 earnings at $2.22 EPS.

Pacira BioSciences (NASDAQ:PCRX) last announced its quarterly earnings data on Wednesday, February 24th. The company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.81 by $0.06. The business had revenue of $130.90 million during the quarter, compared to analyst estimates of $130.91 million. Pacira BioSciences had a return on equity of 10.71% and a net margin of 29.95%. The company’s revenue for the quarter was up 6.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.56 earnings per share.

Other equities analysts have also issued research reports about the company. Royal Bank of Canada lifted their price target on Pacira BioSciences from $65.00 to $70.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 6th. SVB Leerink lowered Pacira BioSciences from an “outperform” rating to a “market perform” rating and boosted their target price for the stock from $63.00 to $75.00 in a research report on Thursday, January 21st. TheStreet lowered Pacira BioSciences from a “b” rating to a “c+” rating in a research report on Thursday, April 8th. HC Wainwright boosted their target price on Pacira BioSciences from $70.00 to $86.00 and gave the stock a “buy” rating in a research report on Monday, March 8th. Finally, Piper Sandler boosted their target price on Pacira BioSciences from $65.00 to $90.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 20th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $75.92.

PCRX opened at $68.26 on Monday. The stock has a 50-day moving average price of $70.92 and a 200-day moving average price of $65.02. The company has a debt-to-equity ratio of 0.78, a current ratio of 7.63 and a quick ratio of 6.84. The firm has a market cap of $2.99 billion, a PE ratio of 24.04, a P/E/G ratio of 0.82 and a beta of 1.27. Pacira BioSciences has a 1 year low of $33.47 and a 1 year high of $80.00.

Hedge funds have recently bought and sold shares of the business. Penserra Capital Management LLC boosted its stake in Pacira BioSciences by 171.9% in the 4th quarter. Penserra Capital Management LLC now owns 995 shares of the company’s stock worth $59,000 after purchasing an additional 629 shares during the period. Amundi Pioneer Asset Management Inc. bought a new position in Pacira BioSciences in the 1st quarter worth approximately $65,000. Strs Ohio boosted its stake in Pacira BioSciences by 228.6% in the 3rd quarter. Strs Ohio now owns 2,300 shares of the company’s stock worth $138,000 after purchasing an additional 1,600 shares during the period. Next Capital Management LLC purchased a new stake in shares of Pacira BioSciences during the 4th quarter worth approximately $209,000. Finally, Kestra Advisory Services LLC purchased a new stake in shares of Pacira BioSciences during the 4th quarter worth approximately $209,000.

In other Pacira BioSciences news, CEO David M. Stack sold 21,250 shares of the company’s stock in a transaction that occurred on Wednesday, February 3rd. The stock was sold at an average price of $71.21, for a total value of $1,513,212.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Roy Winston sold 22,224 shares of the company’s stock in a transaction that occurred on Wednesday, March 31st. The stock was sold at an average price of $70.61, for a total value of $1,569,236.64. Following the completion of the transaction, the insider now owns 48,535 shares of the company’s stock, valued at $3,427,056.35. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 153,306 shares of company stock valued at $11,009,880. 5.80% of the stock is currently owned by corporate insiders.

About Pacira BioSciences

Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure.

Further Reading: Market Capitalization – What it Means for Investors

Earnings History and Estimates for Pacira BioSciences (NASDAQ:PCRX)

Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.